JP2020066629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020066629A5 JP2020066629A5 JP2019189151A JP2019189151A JP2020066629A5 JP 2020066629 A5 JP2020066629 A5 JP 2020066629A5 JP 2019189151 A JP2019189151 A JP 2019189151A JP 2019189151 A JP2019189151 A JP 2019189151A JP 2020066629 A5 JP2020066629 A5 JP 2020066629A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- crystalline form
- methylpiperidin
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 3
- 238000005481 NMR spectroscopy Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 238000001069 Raman spectroscopy Methods 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- -1 7H-pyrrolo[2,3-d]pyrimidin-4-yl Chemical group 0.000 claims 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 230000006720 chronic neuroinflammation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 125000005425 toluyl group Chemical group 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000002689 xenotransplantation Methods 0.000 claims 1
- 125000005023 xylyl group Chemical group 0.000 claims 1
- QRZXLCPZJWWANB-DTWKUNHWSA-N C[C@@H](CC1)NC[C@@H]1Nc1ncnc2c1cc[nH]2 Chemical compound C[C@@H](CC1)NC[C@@H]1Nc1ncnc2c1cc[nH]2 QRZXLCPZJWWANB-DTWKUNHWSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748628P | 2018-10-22 | 2018-10-22 | |
| US62/748628 | 2018-10-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020066629A JP2020066629A (ja) | 2020-04-30 |
| JP2020066629A5 true JP2020066629A5 (enExample) | 2020-07-27 |
| JP6944496B2 JP6944496B2 (ja) | 2021-10-06 |
Family
ID=68343187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019189151A Active JP6944496B2 (ja) | 2018-10-22 | 2019-10-16 | ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12116368B2 (enExample) |
| EP (1) | EP3870584A1 (enExample) |
| JP (1) | JP6944496B2 (enExample) |
| KR (1) | KR102629132B1 (enExample) |
| CN (1) | CN112888691B (enExample) |
| AR (1) | AR116797A1 (enExample) |
| AU (1) | AU2019363840B2 (enExample) |
| BR (1) | BR112021007568A2 (enExample) |
| CA (1) | CA3059000A1 (enExample) |
| IL (1) | IL282446B2 (enExample) |
| MX (1) | MX2021003241A (enExample) |
| SG (1) | SG11202103667QA (enExample) |
| TW (1) | TWI729530B (enExample) |
| WO (1) | WO2020084435A1 (enExample) |
| ZA (1) | ZA202101735B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761011B (zh) | 2019-08-26 | 2024-06-14 | 肯沃斯公司 | 用作jak1抑制剂的取代的(7h-吡咯并[2,3-d]嘧啶-4-基)氨基化合物 |
| AU2020417043A1 (en) * | 2019-12-31 | 2022-06-09 | Pfizer Inc. | Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
| CN113121539A (zh) * | 2019-12-31 | 2021-07-16 | 江苏艾立康医药科技有限公司 | 一种pf06651600的制备方法 |
| CN111620880B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 dl-酒石酸盐，晶型及其制备方法 |
| CN111732591B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 l-酒石酸盐，晶型及其制备方法 |
| CN114835715B (zh) * | 2020-06-15 | 2024-04-05 | 江苏艾立康医药科技有限公司 | Pf-06651600马来酸盐及其制备方法 |
| WO2022012587A1 (zh) * | 2020-07-14 | 2022-01-20 | 苏州晶云药物科技股份有限公司 | 丙烯酮类化合物的丙二酸盐晶型及其制备方法 |
| KR102473645B1 (ko) * | 2020-08-28 | 2022-12-05 | (주)부흥산업사 | (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법 |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| WO2025144783A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Methods of synthesizing substituted pyrrolopyrimidine compounds |
| WO2025146702A1 (en) * | 2024-01-03 | 2025-07-10 | Msn Laboratories Private Limited, R&D Center | Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid |
| CN119060059B (zh) * | 2024-08-21 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种甲苯磺酸利特昔替尼的制备工艺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50087B (sr) | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
| NZ720092A (en) * | 2013-12-05 | 2019-05-31 | Pfizer | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105859721B (zh) * | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
-
2019
- 2019-10-16 JP JP2019189151A patent/JP6944496B2/ja active Active
- 2019-10-17 CA CA3059000A patent/CA3059000A1/en active Pending
- 2019-10-17 TW TW108137470A patent/TWI729530B/zh active
- 2019-10-21 SG SG11202103667QA patent/SG11202103667QA/en unknown
- 2019-10-21 KR KR1020217015125A patent/KR102629132B1/ko active Active
- 2019-10-21 US US17/286,018 patent/US12116368B2/en active Active
- 2019-10-21 CN CN201980069164.0A patent/CN112888691B/zh active Active
- 2019-10-21 MX MX2021003241A patent/MX2021003241A/es unknown
- 2019-10-21 IL IL282446A patent/IL282446B2/en unknown
- 2019-10-21 BR BR112021007568-2A patent/BR112021007568A2/pt unknown
- 2019-10-21 WO PCT/IB2019/058940 patent/WO2020084435A1/en not_active Ceased
- 2019-10-21 EP EP19794259.2A patent/EP3870584A1/en active Pending
- 2019-10-21 AU AU2019363840A patent/AU2019363840B2/en active Active
- 2019-10-22 AR ARP190103015A patent/AR116797A1/es unknown
-
2021
- 2021-03-15 ZA ZA2021/01735A patent/ZA202101735B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020066629A5 (enExample) | ||
| NZ720092A (en) | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | |
| FI4214202T3 (fi) | Cdk4-estäjän kiinteät muodot | |
| JP2013502423A5 (enExample) | ||
| RU2006131591A (ru) | Способ получения 2-аминотиазол-5-ароматических карбоксамидов в качестве ингибиторов киназ | |
| HRP20171610T1 (hr) | Selektivni inhibitori pi3k delta | |
| JP2012505235A5 (enExample) | ||
| BR112021007568A2 (pt) | sal tosilato de pirrolo[2,3-d]pirimidina, forma cristalina do mesmo e processo de fabricação e intermediários para o mesmo | |
| JP2011016800A5 (enExample) | ||
| JP2013530236A5 (enExample) | ||
| JP2020535168A5 (enExample) | ||
| CA2788071A1 (en) | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors | |
| JP2013536259A5 (enExample) | ||
| JP2018514560A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| CA3142088A1 (en) | Compound used as kinase inhibitor and application thereof | |
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| JP2007525494A5 (enExample) | ||
| JP2020521739A5 (enExample) | ||
| AU2022288945B2 (en) | Heteroaryl compounds as inhibitors of tyk2, composition and application thereof | |
| JP2008520712A5 (enExample) | ||
| JP2018502083A5 (enExample) | ||
| JP2024520704A (ja) | アミスルプリドの結晶形態を製造するための方法 | |
| JP2020506906A (ja) | Ｊａｋ酵素阻害剤及びその製造方法と用途 | |
| US10538529B2 (en) | Polymorphic forms of triazolopyrazine derivatives and method of preparing the same |